Pinski J, Schally A V, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P
Endocrine, Polypeptide, and Cancer Institute, Department of Veterans Affairs Medical Center, New Orleans, LA 70146, USA.
J Natl Cancer Inst. 1995 Dec 6;87(23):1787-94. doi: 10.1093/jnci/87.23.1787.
Insulin-like growth factor I (IGF-I) may be involved in the proliferation of human osteosarcomas. Most of the IGF-I found in blood is produced in the liver, where transcription of the IGF-I gene is regulated by growth hormone (GH). Recently, we synthesized various potent antagonists of GH-releasing hormone (GH-RH), including [Ibu0, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGH-RH(1-28)Agm, which is also called MZ-4-71.
We investigated the effects of this antagonist on the growth of the human osteosarcoma cell lines SK-ES-1 and MNNG/HOS, transplanted into nude mice or cultured in vitro.
Nude male mice bearing SK-ES-1 and MNNG/HOS tumors were treated for 4 and 3 weeks, respectively, with MZ-4-71 administered from osmotic minipumps at a dose of 40 micrograms per animal per day. Tumor volume, tumor weight, and levels of receptors for IGF-I were determined. IGF-I levels in serum, tumor, and liver tissue were measured by radioimmunoassay. In other experiments, tumor-bearing nude mice were treated subcutaneously for 3 weeks with the GH-RH agonist hGH-RH(1-29)NH2 or with MZ-4-71 for 13 days at doses of 50 micrograms per animal per day. Effects of MZ-4-71, hGH-RH(1-29)NH2, and human GH (hGH) on cell proliferation and on the production of IGF-I and cyclic adenosine monophosphate were also evaluated in SK-ES-1 and MNNG/HOS cells in vitro.
The growth of SK-ES-1 and MNNG/HOS tumors in nude mice was significantly inhibited by MZ-4-71, as measured by a reduction in tumor volume and weight (all P values < .05). MZ-4-71 treatment of either SK-ES-1 or MNNG/HOS tumor-bearing animals decreased tumor tissue IGF-I levels. The growth of MNNG/HOS xenografts was stimulated by hGH-RH(1-29)NH2 (P < .01). IGF-I levels in serum of tumor-bearing nude mice treated subcutaneously for 13 days with MZ-4-71 were decreased (both P values < .01). High-affinity binding sites for IGF-I were demonstrated on cell membranes of SK-ES-1 and MNNG/HOS tumors. In cell cultures of both osteosarcomas, IGF-I production was stimulated by 25 ng/mL hGH but was not changed by 10 ng/mL hGH-RH(1-29)NH2 or 5 microM MZ-4-71. Incorporation of [3H]thymidine into DNA in SK-ES-1 (but not MNNG/HOS) cells was increased by 25 ng/mL IGF-I (P < .01). The proliferation rate of the two cell lines was not affected by 5-50 ng/mL hGH-RH(1-29)NH2 or 1-80 ng/mL hGH but was suppressed by 10(-6)-10(-5) M MZ-4-71.
Our findings demonstrate that the GH-RH antagonist MZ-4-71 can significantly inhibit the growth of SK-ES-1 and MNNG/HOS osteosarcomas in mice.
胰岛素样生长因子I(IGF-I)可能参与人类骨肉瘤的增殖。血液中发现的大多数IGF-I是由肝脏产生的,其中IGF-I基因的转录受生长激素(GH)调节。最近,我们合成了各种强效的生长激素释放激素(GH-RH)拮抗剂,包括[Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGH-RH(1-28)Agm,它也被称为MZ-4-71。
我们研究了这种拮抗剂对移植到裸鼠体内或体外培养的人类骨肉瘤细胞系SK-ES-1和MNNG/HOS生长的影响。
携带SK-ES-1和MNNG/HOS肿瘤的雄性裸鼠分别用渗透微型泵以每天每只动物40微克的剂量给予MZ-4-71处理4周和3周。测定肿瘤体积、肿瘤重量和IGF-I受体水平。通过放射免疫测定法测量血清、肿瘤和肝组织中的IGF-I水平。在其他实验中,携带肿瘤的裸鼠皮下注射GH-RH激动剂hGH-RH(1-29)NH2或MZ-4-71,剂量为每天每只动物50微克,持续3周或13天。还在体外评估了MZ-4-71、hGH-RH(1-29)NH2和人生长激素(hGH)对SK-ES-1和MNNG/HOS细胞增殖以及IGF-I和环磷酸腺苷产生的影响。
通过肿瘤体积和重量的减少来衡量,MZ-4-71显著抑制了裸鼠体内SK-ES-1和MNNG/HOS肿瘤的生长(所有P值<.05)。用MZ-4-71处理携带SK-ES-1或MNNG/HOS肿瘤的动物会降低肿瘤组织中的IGF-I水平。hGH-RH(1-29)NH2刺激了MNNG/HOS异种移植物的生长(P<.01)。皮下注射MZ-4-71 13天的携带肿瘤裸鼠血清中的IGF-I水平降低(两个P值<.01)。在SK-ES-1和MNNG/HOS肿瘤的细胞膜上证明了存在IGF-I的高亲和力结合位点。在两种骨肉瘤的细胞培养中,25 ng/mL的hGH刺激了IGF-I的产生,但10 ng/mL的hGH-RH(1-29)NH2或5 microM的MZ-4-71对其没有影响。25 ng/mL的IGF-I增加了[3H]胸腺嘧啶掺入SK-ES-1细胞(但不包括MNNG/HOS细胞)DNA中的量(P<.01)。两种细胞系的增殖率不受5-50 ng/mL的hGH-RH(1-29)NH2或1-80 ng/mL的hGH影响,但受到10(-6)-10(-5) M的MZ-4-71抑制。
我们的研究结果表明,GH-RH拮抗剂MZ-4-71可以显著抑制小鼠体内SK-ES-1和MNNG/HOS骨肉瘤的生长。